A labile sodium pump inhibitor from the peritoneal dialysate of hypertensive renal failure patients: estimates of potency.
Estimations of concentration of the labile sodium pump inhibitor isolated from human peritoneal dialysate were made using supercritical fluid chromatography coupled to flame ionization detection to determine the quantity of this factor in half of a purified preparation of the factor compared to the bioactivity of the other half in different assays. Ouabain was used for comparison. The labile factor appeared to be 30 times more effective than ouabain against canine renal [Na,K]ATPase. Moreover, this same factor appeared to be approximately 1,000 times more potent than ouabain in causing vascular smooth muscle contraction. The differences between this labile sodium pump inhibitor and ouabain most likely reflect their respective binding affinities. The assay differences in half maximal response to the labile sodium pump inhibitor may be due to differences in sodium pump alpha isoform sensitivity.
Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
S W
SW
Graves
Q F
QF
Tao
K E
KE
Markides
G H
GH
Williams
N K
NK
Hollenberg
D000818:Animals; D001013:Aorta, Thoracic; D002851:Chromatography, High Pressure Liquid; D015314:Dialysis Solutions / Q000737:chemistry*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000302:isolation & purification* / Q000494:pharmacology; D006801:Humans; D006977:Hypertension, Renal / Q000628:therapy*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D010042:Ouabain / Q000494:pharmacology; D010530:Peritoneal Dialysis; D011817:Rabbits; D051437:Renal Insufficiency / Q000628:therapy*; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors* / Q000378:metabolism
D015314:Dialysis Solutions; D004791:Enzyme Inhibitors; D010042:Ouabain; D000254:Sodium-Potassium-Exchanging ATPase